Moss Genomics (XCNQ:MOSS) Change In Receivables : C$-0.01 Mil (TTM As of Mar. 2025)

View and export this data going back to 2023. Start your Free Trial

What is Moss Genomics Change In Receivables?

Moss Genomics's change in receivables for the quarter that ended in Mar. 2025 was C$-0.00 Mil. It means Moss Genomics's Accounts Receivable increased by C$0.00 Mil from Dec. 2024 to Mar. 2025 .

Moss Genomics's change in receivables for the fiscal year that ended in Jun. 2023 was C$-0.01 Mil. It means Moss Genomics's Accounts Receivable increased by C$0.01 Mil from Jun. 2022 to Jun. 2023 .

Moss Genomics's Accounts Receivable for the quarter that ended in Mar. 2025 was C$0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Moss Genomics's liquidation value for the three months ended in Mar. 2025 was C$-0.15 Mil.

Moss Genomics Change In Receivables Historical Data

The historical data trend for Moss Genomics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moss Genomics Change In Receivables Chart

Moss Genomics Annual Data

Trend

Jun22

Jun23

Change In Receivables

-0.01

Moss Genomics Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Sep24	Dec24	Mar25
Change In Receivables	Get a 7-Day Free Trial								-	-	-	-	-

Moss Genomics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.01 Mil.

Moss Genomics (XCNQ:MOSS) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Moss Genomics's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Moss Genomics's accounts receivable are only considered to be worth 75% of book value:

Moss Genomics's liquidation value for the quarter that ended in Mar. 2025 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.043	-	0.188	+	0.75 * 0	+	0.5 * 0
=	-0.15

Moss Genomics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Moss Genomics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Moss Genomics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Moss Genomics Inc (XCNQ:MOSS) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

F73:Germany

Address

1030 West Georgia Street, Suite 908, Vancouver, BC, CAN, V6E 2Y3

Website

https://www.mossgenomics.com

Moss Genomics Inc is an emerging consumer genomics company that provides personalized health, anti-aging, and wellness solutions based on genomic, microbiome, and epigenome data. The company aims to eliminate barriers in healthcare by offering accessible, affordable at-home testing along with easy-to-understand actionable results.

Executives

Hunter Jordan	Director
Lucas Cahill	10% Security Holder

Moss Genomics Headlines

No Headlines